Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study - PubMed (original) (raw)

doi: 10.1093/jac/dkp180. Epub 2009 May 25.

Affiliations

PMID: 19468027
DOI: 10.1093/jac/dkp180

Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study

Oriol Mitjà et al. J Antimicrob Chemother. 2009 Aug.

Abstract

Objectives: Gentamicin is often used to treat listeriosis, particularly in patients with meningitis; nonetheless, some clinicians question this practice because of the drug's associated nephrotoxicity and inability to cross the blood-brain barrier. The aim of this study was to evaluate predictors of mortality and the impact of aminoglycosides on outcome in patients with listeriosis.

Methods: We conducted a retrospective study of all non-pregnant adult patients with Listeria monocytogenes infection detected in sterile body fluids between 1983 and 2006. Early mortality was defined as death occurring between days 3 and 14 after admission, and late mortality as in-hospital death after 14 days.

Results: Of 118 episodes, 16 were excluded because patients died in the first 48 h. Among the 102 patients analysed, 33 (32%) had received combined beta-lactam and aminoglycoside therapy and 69 (68%) beta-lactam monotherapy. Both groups had similar demographic and clinical features, and rate of appropriate initial therapy. Overall mortality was 21/102 (20.6%). Early overall mortality was 11.8%: 27.3% (9/33) in the combined group and 4.3% (3/69) in the monotherapy group (P = 0.003). Late mortality was 8.8%. In the multivariate analysis, the factors predicting early mortality were renal failure, previous corticosteroid therapy and age >65 years, whereas neoplastic disease and coma were associated with late mortality. Gentamicin administration did not decrease early mortality, but seemed to increase it. In the late mortality analysis, gentamicin use had no impact. In an analysis with the propensity score method for the use of aminoglycosides, combined therapy with this antibiotic was associated with an increasing trend for early mortality (OR 3.40, 95% CI 0.82-14.07).

Conclusions: The addition of aminoglycosides to treatment for listeriosis did not improve the patients' outcome.

PubMed Disclaimer

Cited by

Clinical and microbiological characteristics and follow-up of invasive Listeria monocytogenes infection among hospitalized patients: real-world experience of 16 years from Hungary.
Kiss R, Marosi B, Korózs D, Petrik B, Lakatos B, Szabó BG. Kiss R, et al. BMC Microbiol. 2024 Sep 6;24(1):325. doi: 10.1186/s12866-024-03478-z. BMC Microbiol. 2024. PMID: 39242991 Free PMC article.
COVID-19 and Listeria Meningitis Treated by Ampicillin, Sulfamethoxazole/Trimethoprim and Meropenem.
Seki M, Karaushi H, Arai N, Hayashi T, Mitsutake K. Seki M, et al. Infect Drug Resist. 2023 Jul 3;16:4289-4295. doi: 10.2147/IDR.S414879. eCollection 2023. Infect Drug Resist. 2023. PMID: 37424669 Free PMC article.
A case report of oral sulfamethoxazole in the treatment of posttransplant Listeria monocytogenes meningitis.
Ma Y, Hu W, Song W. Ma Y, et al. Transl Androl Urol. 2023 Mar 31;12(3):524-529. doi: 10.21037/tau-23-83. Epub 2023 Mar 27. Transl Androl Urol. 2023. PMID: 37032758 Free PMC article.
Primary spontaneous listerial peritonitis.
Tholany J, Samra H, Kobayashi T, Prasidthrathsint K. Tholany J, et al. IDCases. 2023 Mar 16;32:e01748. doi: 10.1016/j.idcr.2023.e01748. eCollection 2023. IDCases. 2023. PMID: 36974133 Free PMC article.
Human Listeriosis.
Koopmans MM, Brouwer MC, Vázquez-Boland JA, van de Beek D. Koopmans MM, et al. Clin Microbiol Rev. 2023 Mar 23;36(1):e0006019. doi: 10.1128/cmr.00060-19. Epub 2022 Dec 8. Clin Microbiol Rev. 2023. PMID: 36475874 Free PMC article. Review.

Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study - PubMed (original) (raw)